Results 81 to 90 of about 33,432 (282)
Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
Diabetes Care, 2011 Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h of awakening is believed to augment low hypothalamic ...
R. DeFronzo
semanticscholar +1 more source
ESC Heart Failure, Volume 12, Issue 6, Page 4521-4526, December 2025.Abstract Aims The diagnosis of peripartum cardiomyopathy (PPCM) is often delayed due to the absence of disease‐specific biomarkers. Recently, serum proteins—QSOX1, adiponectin (ADIPOQ) and ITIH3—have shown potential for improving diagnostic accuracy, especially when used with NT‐proBNP.
Vitaris Kodogo +13 more
wiley +1 more source
Pituitary adenomas, some diagnostic and therapeutical aspects [PDF]
, 1994 The treatment of almost all types of pituitary adenomas has changed considerably in recent years. New types of drugs as well as improved application forms of older drug therapies are now becoming more and more available for everyday treatment of patients
Herder, W.W. (Wouter) de +2 more
core +1 more source
MedComm, Volume 6, Issue 12, December 2025.Role of neurotransmitters in multiple pathological processes. Various neurotransmitters, including ACh, EPI, NE, 5‐HT, histamine, DA, glutamate, GABA, and neuropeptides participate in regulating key pathological events, including tumor proliferation, tumor migration, remodeling of the immune microenvironment, and the development of NDDs and ...
Gege Li +13 more
wiley +1 more source
Acromegaly: pathogenesis & treatment [PDF]
, 2019 Acromegaly is a multi-system disorder whose etiology is most often traced back to a growth hormone-secreting pituitary adenoma (PA). Growth hormone (GH) secretion promotes insulin-like growth factor 1 (IGF-1) release from peripheral tissues, leading to ...
Tilvawala, Megha
core
Molecular Genetics &Genomic Medicine, Volume 13, Issue 12, December 2025.In the present study, a de novo variant of the CSNK2A1 gene, designated c.149A>G (p.Tyr50Cys), was identified in a subject diagnosed with OCNDS by WES. The molecular mechanism by which this variant leads to a wide range of clinical phenotypes by disrupting the kinase domain function was elucidated through a combination of experimental investigation and
Xin Li +6 more
wiley +1 more source
Dopa-responsive dystonia and hyperprolactinaemia : a novel association in two sisters [PDF]
, 2007 Dopa-Responsive Dystonia (DRD) is a rare hereditary condition of childhood-onset dystonia which responds dramatically to treatment with levodopa. It was first described in 1971 as a "hereditary progressive basal ganglia disease with marked diurnal ...
Cachia, Mario J., Galea, Janabel
core
Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
Frontiers in Neuroscience, 2012 Being quick often comes at the expense of being accurate. This speed–accuracy tradeoff is a central feature of many types of decision making. It has been proposed that dopamine plays an important role in adjusting responses between fast and accurate ...
J. Winkel +6 more
semanticscholar +1 more source
The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
British Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +206 more
wiley +1 more source